A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 4, 2003, Pages 555-561

  Weinstock, Marta ^a   Gorodetsky, Elena ^a   Poltyrev, Tatyana ^a   Gross, Aviva ^b   Sagi, Yotam ^b   Youdim, Moussa ^b  

^a HEBREW UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antidepressant activity; Brain selective MAO inhibition; Cholinesterase inhibition; Dementia of Alzheimer and Lewy body types; Neuroprotection; Nigrostriatal dopamine

Indexed keywords

(N PROPARGYLAMINOINDAN 5 YL)ETHYLMETHYLCARBAMATE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; NEUROTOXIN; PEROXYNITRITE; RASAGILINE; RIVASTIGMINE; TYRAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL CULTURE; COMORBIDITY; CYTOTOXICITY; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME INHIBITION; FORCED SWIMMING TEST; HUMAN; LEWY BODY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NEUROPROTECTION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RABBIT; RAT; REVIEW; SMALL INTESTINE;

EID: 0038012567     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00053-8     Document Type: Review

References (58)

1. Aarsland D., Ballard C., McKeith I., Perry R.H., Larsen J.P. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. J. Neuropsychiatry Clin. Neurosci. 13:2001;374-379.
2. Arnaiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport. 26:2001;851-855.
3. Birkmayer W., Riederer P., Youdim M.B., Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J. Neural Transm. 36:1975;303-326.
4. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1:1977;439-443.
5. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology. 94:1988;147-160.
6. Cassarino D.S., Bennett J.P. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Rev. 29:1999;1-25.
7. Collins G.G., Sandler M., Williams E.D., Youdim M.B.H. Multiple forms of human brain mitochondrial monoamine oxidase. Nature. 225:1970;817-820.
8. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
9. Da Prada M., Zurcher G., Wuthrich I., Haefely W.E. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transm. 26:1988;31-56. (Suppl.).
10. Ebmeier K.B., Hunter R., Curran S.M., Dougal N.J., Murray C.L., Wyper D.J., Patterson J., Hanson M.T., Siegfried K., Goodwin G.M. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional blood flow in Alzheimer's disease. Psychopharmacology. 108:1992;103-109.
11. Eliash S., Speizer Z., Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural. Transm. 108:2001;909-923.
12. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 57:2001;613-620.
13. Filip V., Kolibas E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J. Psychiatry Neurosci. 24:1999;234-243.
14. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 18:2001;891-898.
15. Gordon C.J. Thermoregulation in laboratory mammals and humans exposed to anticholinesterase agents. Neurotoxicol. Teratol. 16:1994;427-453.
16. Gsell W., Conrad R., Hickethier M., Sofic E., Frolich L., Wichart I., Jellinger K., Moll G., Ransmayr G., Beckmann H. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem. 64:1995;1216-1223.
17. Harkins S.W., Taylor J.R., Mattay V., Regelson W. Tacrine treatment in Alzheimer's disease enhances cerebral blood flow and mental status and decreases caregiver suffering. Ann. N. Y. Acad. Sci. 826:1997;472-474.
18. Heikkila R.E., Duvoisin R.C., Finberg J.P., Youdim M.B. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116:1985;313-317.
19. Honig L.S., Mayeux R. Natural history of Alzheimer's disease. Aging (Milano). 13:2001;171-182.
20. Huang W., Chen Y., Shohami E., Weinstock M. Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366:1999;127-135.
21. Jann M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 20:2000;1-12.
22. Lahtinen H., Koistinaho J., Kauppinen R., Haapalinna A., Keinanen R., Sivenius J. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 757:1997;260-267.
23. Le W., Jankovic J., Xie W., Kong R., Appel S.H. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci. Lett. 224:1997;197-200.
24. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop. Neurology. 47:1996;1113-1124.
25. Mega M.S., Masterman D.M., O'Connor S.M., Barclay T.R., Cummings J.L. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch. Neurol. 56:1999;1388-1393.
26. Moretti R., Torre P., Antonello R.M., Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur. Neurol. 8:2001;361-362.
27. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:1994;2179-2184.
28. Newman S.C. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J. Affect. Disord. 52:1999;169-176.
29. O'Carroll A.M., Fowler C.J., Phillips J.P., Tobbia I., Tipton K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedeberg's Arch. Pharmacol. 322:1983;198-202.
30. Oxman T.E. Antidepressants and cognitive impairment in the elderly. J. Clin. Psychiatry. 57(Suppl. 5):1996;38-44.
31. Palmer A.M., Stratman G.C., Procter A.W., Bowen D.M. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol. 23:1988;616-620.
32. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
33. Perry R.H., Irving D., Blessed G., Fairbairn A., Perry E.K. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J. Neurol. Sci. 95:1991;119-139.
34. Porsolt R.D., Bertin A., Blavet N., Deniel M., Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 57:1979;201-210.
35. Potkin S.G., Anand R., Fleming K., Alva G., Keator D., Carreon D., Messina J., Wu J.C., Hartman R., Fallon J.H. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4:2001;223-230.
36. Przuntek H., Conrad B., Dichgans J., Kraus P.H., Krauseneck P., Pergande G., Rinne U., Schimrigk K., Schnitker J., Vogel H.P. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur. J. Neurol. 6:1999;141-150.
37. Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., Inzelberg R., Djaldetti R., Klein C., Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23:2000;324-330.
38. Robert P. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr. Med. Res. Opin. 18:2002;117-156.
39. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Co-operative Study. N. Engl. J. Med. 336:1997;1216-1222.
40. Saura J., Luque J.M., Cesura A.M., Da Prada M., Chan-Palay V., Huber G., Loffler J., Richards J.G. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography. Neuroscience. 62:1994;15-30.
41. Simpson I.A., Chundu K.R., Davies-Hill T., Honer W.G., Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35:1994;546-551.
42. Snyder S.H., D'Amato R.J. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology. 36:1986;250-258.
43. Tandberg E., Larsen J.P., Aarsland D., Cummings J.L. The occurrence of depression in Parkinson's disease. A community-based study. Arch. Neurol. 53:1996;175-179.
44. Terry R.D. The pathogenesis of Alzheimer's disease. Fisher A., Hanin I., Yoshida M. Progress in Alzheimer's and Parkinson's Diseases. 1998;1-7 Plenum, New York.
45. Tsolaki M., Kokarida K., Iakovidou V., Stilopoulos E., Meimaris J., Kazis A. Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am. J. Alzheimer's Dis. Other Dement. 16:2001;268-278.
46. Wang R.H., Schorer-Apelbaum D., Weinstock M. Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine. Eur. J. Pharmacol. 433:2001;73-79.
47. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 12:1999;307-323.
48. Weinstock M., Bejar C., Wang R.H., Poltyrev T., Gross A., Finberg J.P.M., Youdim M.B.H. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural. Transm. 60:2000;157-169. (Suppl.).
49. Weinstock M., Goren T., Youdim M.B.H. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. 50:2000;216-222.
50. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B.H., Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N. Y. Acad. Sci. 939:2001;148-162.
51. Weinstock M., Gorodetsky E., Wang R.H., Fross A., Weinreb O., Youdim M.B.H. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacol. 43:2002;999-1005.
52. Weinstock M., Poltyrev T., Bejar C., Sagi Y., Youdim M.B.H. TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer's disease with co-morbidity of Parkinson's disease and depression. Mizuno Y., Fisher A., Hanin I. Mapping the progress of Alzheimer's and Parkinson's disease. 2002;199-204 Kluwer Academic/Plenum Publishers, New York.
53. Weinstock M., Poltyrev T., Bejar C., Youdim M.B.H. Effect of TV3326, a novel monoamine-oxidase-cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology. 160:2002;318-324.
54. Wu R.M., Chen R.C., Chiueh C.C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. N. Y. Acad. Sci. 899:2000;255-261.
55. Yang H.Y., Neff N.H. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharmacol. Exp. Ther. 189:1974;733-740.
56. Yogev-Falach M., Amit T., Bar-Am O., Weinstock M., Youdim M.B.H. The involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16:2002;1674-1676.
57. Youdim M.B.H., Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Biol. 21:2001;555-573.
58. Youdim M.B.H., Gross A., Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132:2001;500-506.